A Study to Assess Adverse Events and Change in Disease State of Intravenously (IV) Infused Etentamig (ABBV-383) of Adult Participants With Relapsed or Refractory Multiple Myeloma in Japan
Clinical trial NCT05286229 · ACTIVE_NOT_RECRUITING
Trial details
- NCT number
- NCT05286229
- Sponsor
- AbbVie
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- Phase 1
- Study type
- INTERVENTIONAL
- Start date
- 2022-03-24
- Primary completion
- 2026-03-01
- Enrollment
- 8
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.